利拉鲁肽(Liraglutide) - 药物靶点：GLP-1R_在研适应症：肥胖，超重，2型糖尿病_专利_临床

概要

基本信息

药物类型

重组多肽

别名

Liraglutide (Genetical Recombination)、Liraglutide Recombinant、Saxenda

+ [18]

靶点

GLP-1R

作用机制

GLP-1R激动剂(胰高血糖素样肽-1激动剂)

治疗领域

内分泌与代谢疾病

在研适应症

肥胖超重2型糖尿病

非在研适应症

暴食症心血管疾病非胰岛素依赖型糖尿病2+ [11]

原研机构

Novo Nordisk A/S

在研机构

Novo Nordisk A/SNovo Nordisk, Inc.

非在研机构-

最高研发阶段批准上市

首次获批日期

欧盟 (2009-06-30),

2型糖尿病

最高研发阶段(中国)批准上市

特殊审评-

登录后查看首次获批时间轴

序列信息

Sequence Code 50953

来源: *****

关联

425

项与利拉鲁肽相关的临床试验

NCT06171152 / Not yet recruiting早期临床1期IIT

Examining the Utility of GLP-1 Agonists as Neuroprotective Agents Through a Pilot Clinical Trial in High Risk Population With Neurocognitive Deficits and Obesity

This study is for people who have multiple sclerosis, acute leukemia (in remission), or long-COVID and a Body Mass Index over 27 and may struggle with cognitive issues such as remembering information, concentrating, or making decisions that affect everyday life.
By doing this study, researchers hope to learn how liraglutide (Saxenda®), a weight loss drug, affects levels of a certain disease marker in the body called Brain Derived Neurotrophic Factor (BDNF). Participation in this research will last about 21 weeks.

开始日期2024-11-01

申办/合作机构

The University of Chicago

ChiCTR2400086382 / Suspended临床4期IIT

Safety and efficacy of GLP-1RA combined with Banxia Xiexin Decoction in the treatment of type 2 diabetes

开始日期2024-07-15

申办/合作机构-

NCT06439056 / Recruiting临床1期

An Open, Single Ascending Dose, Phase 1 Study to Assess the Pharmacokinetics, Safety, and Tolerability of NEX-22A, a Subcutaneous Prolonged-release Injection, in Male and Female Participants With Type 2 Diabetes

The purpose with the study is to assess pharmacokinetics of NEX-22A in patients with type 2 diabetes.

开始日期2024-05-27

申办/合作机构

Nanexa AB

[+1]

100 项与利拉鲁肽相关的临床结果

登录后查看更多信息

100 项与利拉鲁肽相关的转化医学

登录后查看更多信息

100 项与利拉鲁肽相关的专利（医药）

登录后查看更多信息

3,742

项与利拉鲁肽相关的文献（医药）

2024-04-19·The Journal of clinical endocrinology and metabolism

Glycemia and Gluconeogenesis With Metformin and Liraglutide: A Randomized Trial in Youth-onset Type 2 Diabetes

Article

作者: Walter, Mary ; Cogen, Fran ; Chen, Kong Y ; Estrada, D Elizabeth ; Yang, Shanna ; Ha, Joon ; Magge, Sheela N ; Shouppe, Eileen ; Kasturi, Kannan ; Peer, Cody ; Krenek, Andrea ; Davis, Faith S ; Zeng, Yi ; Turner, Sara ; Walter, Peter J ; Dietsche, Katrina B ; Cai, Hongyi ; Brychta, Robert J ; Mabundo, Lilian ; Chung, Stephanie T ; Chacko, Shaji ; Sherman, Arthur S ; Courville, Amber B ; Figg, William ; Chowdhury, Aruba ; Dixon, Sydney A ; Stagliano, Michael

Abstract:

Objective:

Elevated rates of gluconeogenesis are an early pathogenic feature of youth-onset type 2 diabetes (Y-T2D), but targeted first-line therapies are suboptimal, especially in African American (AA) youth. We evaluated glucose-lowering mechanisms of metformin and liraglutide by measuring rates of gluconeogenesis and β-cell function after therapy in AA Y-T2D.

Methods:

In this parallel randomized clinical trial, 22 youth with Y-T2D—age 15.3 ± 2.1 years (mean ± SD), 68% female, body mass index (BMI) 40.1 ± 7.9 kg/m2, duration of diagnosis 1.8 ± 1.3 years—were randomized to metformin alone (Met) or metformin + liraglutide (Lira) (Met + Lira) and evaluated before and after 12 weeks. Stable isotope tracers were used to measure gluconeogenesis [2H2O] and glucose production [6,6-2H2]glucose after an overnight fast and during a continuous meal. β-cell function (sigma) and whole-body insulin sensitivity (mSI) were assessed during a frequently sampled 2-hour oral glucose tolerance test.

Results:

At baseline, gluconeogenesis, glucose production, and fasting and 2-hour glucose were comparable in both groups, though Met + Lira had higher hemoglobin A1C. Met + Lira had a greater decrease from baseline in fasting glucose (−2.0 ± 1.3 vs −0.6 ± 0.9 mmol/L, P = .008) and a greater increase in sigma (0.72 ± 0.68 vs −0.05 ± 0.71, P = .03). The change in fractional gluconeogenesis was similar between groups (Met + Lira: −0.36 ± 9.4 vs Met: 0.04 ± 12.3%, P = .9), and there were no changes in prandial gluconeogenesis or mSI. Increased glucose clearance in both groups was related to sigma (r = 0.63, P = .003) but not gluconeogenesis or mSI.

Conclusion:

Among Y-T2D, metformin with or without liraglutide improved glycemia but did not suppress high rates of gluconeogenesis. Novel therapies that will enhance β-cell function and target the elevated rates of gluconeogenesis in Y-T2D are needed.

2024-04-01·The American journal of emergency medicine

GLP-1 agonists: A review for emergency clinicians

Review

作者: Koyfman, Alex ; Pelletier, Jessica ; Long, Brit ; Bridwell, Rachel E

INTRODUCTION:

Glucagon-like peptide 1 (GLP-1) based therapies, including GLP-1 agonists, are currently in use for treatment of diabetes and obesity. However, several complications may occur with their use.

OBJECTIVE:

This narrative review provides a focused evaluation of GLP-1 agonist therapy and associated complications for emergency clinicians.

DISCUSSION:

GLP-1 agonists potentiate insulin release and reduce gastric emptying and food intake. These agents have demonstrated significant improvements in glucose control in diabetics and weight loss in obese patients. The two most common agents include subcutaneous semaglutide (Ozempic, approved for type 2 diabetes, and Wegovy, approved for weight loss) and liraglutide (Saxenda, approved for weight loss, and Victoza, approved for type 2 diabetes), though an oral formulation of semaglutide is available (Rybelsus). While these drugs are associated with improved long-term outcomes, there are a variety of associated adverse events. The most common include gastrointestinal (GI) adverse events such as nausea, vomiting, diarrhea, and abdominal pain. Pancreatitis and biliary disease may also occur. Hypersensitivity including injection site reactions have been associated with use, with reports of anaphylaxis and other rashes. Renal adverse events are most commonly associated with severe GI losses. Hypoglycemia may occur when these agents are used with sulfonylureas or insulin. There is also an increased risk of diabetic retinopathy. Due to the current shortage and expense of these medications, many patients have attempted to obtain these medications from non-licensed and unregulated agents, which may be associated with increased risk of serious complications.

CONCLUSIONS:

An understanding of the indications for GLP-1 agonist use and associated adverse events can assist emergency clinicians.

2024-04-01·The Annals of pharmacotherapy

Incretin Analogs for Weight Management in Adults Without Diabetes

Review

作者: Lobkovich, Alison ; Lipari, Melissa ; Kale-Pradhan, Pramodini

Objective::

This is a narrative review of incretin analogs and their effect on weight management in adult without diabetes.

Data Sources::

Randomized controlled trials were identified by English language. PubMed/MEDLINE, Scopus, and Embase databases were searched from inception through June 2023 to identify all pertinent trials reporting outcomes on efficacy and safety search using the terms: tirzepatide, semaglutide, liraglutide, and obesity.

Study Selection and Data Extraction::

Selected studies were included if the study population was composed of adults without diabetes being treated by glucagon-like peptide 1 (GLP-1) receptor agonists or glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 agonists for weight management, and weight loss was assessed as a primary outcome.

Data Synthesis::

Fifteen studies involving 3 pharmacotherapies (liraglutide, semaglutide, and tirzepatide) were identified. Efficacy data supporting the use of these agents for weight management were promising when compared to placebo and/or other behavioral therapies. Percent weight loss ranged from 5.7% to 11.8%, 14.9% to 17.4%, and 15% to 20.9% for liraglutide, semaglutide, and tirzepatide, respectively. Safety data were relatively similar across all trials and identified gastrointestinal adverse effects as most common.

Relevance to Patient Care and Clinical Practice::

Glucagon-like peptide 1 agonists are preferred for overweight or obese patients by the American Gastroenterological Association. Future guidelines may address tirzepatides’ place in therapy as new evidence comes forth. Providers should consider patient-specific factors such as cost, adverse effects, drug interactions, and comorbidities when prescribing these agents and provide education regarding the need for concurrent diet and exercise modifications.

Conclusions::

All incretin analogs in this review are superior to placebo when used for weight management in adults without diabetes.

952

项与利拉鲁肽相关的新闻（医药）

2024-07-22

·drugs

2011 to 2023 Saw Increase in New GLP-1 Receptor Agonist Prescriptions

MONDAY, July 22, 2024 -- From 2011 to 2023, there was an increase in new glucagon like peptide 1 receptor agonist (GLP-1RA) prescriptions, according to a research letter published online July 23 in the Annals of Internal Medicine . Yee Hui Yeo, M.D., from Cedars-Sinai Medical Center in Los Angeles, and colleagues examined nationwide trends in GLP-1RA prescription patterns, stratified by indications, using data from a federated health research network with deidentified records of about 45 million persons. The researchers found that the 1 million new GLP-1RA users were disproportionately female, non-Hispanic White, and those with a body mass index (BMI) of ≥30 kg/m 2 . Age- and sex-standardized incidence of new GLP-1RA use increased during 2011 to 2023, especially after 2020. When categorized by indication, the proportion of new GLP-1RA users with type 2 diabetes decreased. However, a twofold increase was seen in the proportion of users without type 2 diabetes, but with a BMI of ≥30 kg/m 2 , or those with a BMI of 27 to 30 kg/m 2 and an obesity-related comorbid condition during the same period. From 2019 to 2023, the proportion of users without U.S. Food and Drug Administration-approved indications increased from 0.21 to 0.37 percent. In 2019, semaglutide and liraglutide accounted for 31.4 and 35.3 percent of all new GLP-1RA prescriptions, while these proportions were 88.1 and 10.3 percent, respectively, in 2023. "We revealed rising trends in prescribing GLP-1RAs, particularly among users with obesity," the authors write. "These findings call for strategies to address the growing demand and ensure equitable access to GLP-1RAs."

2024-07-21

·Insight数据库

重磅！礼来「减肥针」国内最新获批，司美的最强对手来了？

本文作者：云也 19 日，明星药替尔泊肽注射液「长期体重管理」适应症，获得国家药品监督管理局批准。[1] 图源：国家药监局官网第一季度，替尔泊肽合计收入 23.24 亿美元，占礼来总营收的 26%。加上司美格鲁肽一季度超 60 亿美元的成绩，以这「双巨头」为代表的 GLP-1 受体激动剂延续着几年来的火爆。以「减肥针」之名，「双巨头」在国内早已火爆多年。自从 5 月 21 日替尔泊肽在国内获批用于降糖、6 月 25 日司美格鲁肽国内获批用于减重，替尔泊肽减重适应症何时能在国内获批，一直备受关注。随着这次减重适应症获批，「双巨头」终于正式在国内减重市场聚首了。火爆全球，平均减重高达 26.6% 替尔泊肽是目前首个且目前唯一获批的葡萄糖依赖性促胰岛素多肽（GIP）/胰高糖素样肽-1（GLP-1）受体激动剂。 GLP-1 是一种肠促胰素，以葡萄糖浓度依赖的方式促进胰岛素分泌，抑制胰高糖素分泌从而降低血糖，同时能延缓胃排空，因此兼具减重效果。替尔泊肽可结合并激活 GIP 受体和 GLP-1 受体，通过调节食欲来减少食物摄入、降低体重和减少脂肪量。本次获批的减重适应症为，在控制饮食和增加运动基础上，体重指数（BMI）符合以下要求的成人的长期体重管理：≥28 kg/m²（肥胖），或 ≥24 kg/m²（超重）并伴有至少一种体重相关合并症（如：高血压、血脂异常、高血糖、阻塞性睡眠呼吸暂停、心血管疾病等）。图源：礼来替尔泊肽最早于 2022 年 5 月获得美国食品和药物管理局（FDA）批准用于改善成人 2 型糖尿病患者，后陆续在欧盟、日本等获批。2023 年 11 月，FDA 的批准让替尔泊肽正式进入慢性体重管理市场。今年 5 月 21 日，国家药监局依据 5 项全球 Ⅲ 期研究——SURPASS 系列临床试验，和一项亚太地区 Ⅲ 期研究—— SURPASS-AP-Combo 临床试验（受试者 83.4% 为中国患者），批准了替尔泊肽用于 2 型糖尿病患者降糖治疗[2]。 SURPASS 1～5 研究数据结果而在减重方面，替尔泊肽在 Ⅲ 期临床取得了 72 周体重平均减轻 21.1%，到 84 周（72+12 周的强化生活方式干预），替尔泊肽治疗的总平均体重减轻高达 26.6%（29.2kg）的重磅结果 [3,4]。 5 月 31 日，首个中国多中心替尔泊肽治疗超重和肥胖的有效性和安全性研究（SURMOUNT-CN）结果也在 JAMA 上发表。 SURMOUNT-CN 纳入肥胖（BMI≥28kg/m²）或伴有至少一种合并症的超重（BMI≥24kg/m²）中国成人，在低热量饮食和增加运动的基础上，对比替尔泊肽与安慰剂在体重减轻方面的有效性和安全性。图源：参考资料 5 研究结果显示：第 52 周，10mg 组、15mg 组平均体重分别降低 13.6%（12.3kg）、17.5%（16.1kg），均优于安慰剂组的 2.3%（2.1kg）。平均腰围自基线分别减少 11.4 cm、14.5cm，优于安慰剂组的 2.6cm。在安全性上，治疗期间最常见的不良事件依旧是胃肠道反应，大多数患者为轻度至中度，很少发生导致停止治疗的不良事件（<5%）。同时，治疗组的心血管代谢指标，包括空腹血糖、胰岛素、极低密度脂蛋白胆固醇、甘油三酯、收缩压和舒张压，相比安慰剂组都得到显著改善。百亿市场，竞争刚刚开始现象级药物，常带来一个领域的飞升。摩根大通去年曾预期，在司美格鲁肽和替尔泊肽「双巨头」的推动下，2030 年这类药的年销售额将超 1000 亿美元。仅仅半年后，BMO Capital Markets 就又把预期推到了 1500 亿美元 [6]。图源：参考资料 6 而有着如此庞大人口基数，我国市场更是兵家必争。根据弗若斯特沙利文预测，我国 GLP-1 药物的市场规模到 2030 年将超过 500 亿元。目前，替尔泊肽国内定价暂未公布，在美国每月治疗标价（4 支）约为 974 美元（约合人民币 7,047 元）。今年第一季度，诺和诺德司美格鲁肽 3 款产品爆卖超 60 亿美元，而礼来替尔泊肽合计收入也达到 23.24 亿美元，占礼来总营收的 26%。从利拉鲁肽、度拉糖肽到司美格鲁肽、替尔泊肽，GLP-1 受体激动剂类药物的火爆之路，处于领先地位的「双巨头」无疑是目前的最大获益者。如今，中国 GLP-1 受体激动剂类药物的市场，却也不只是「双巨头」的天下。除了礼来和诺和诺德，国内企业也在 GLP-1 类药物上纷纷发力，恒瑞医药、石药集团、信达生物、华东医药等都有布局。今年 5 月，恒瑞医药刚刚宣布其具有自主知识产权的 GLP-1 类创新药除大中华区以外的全球范围内开发、生产和商业化的独家权利，以 60 亿美元超高价完成出海交易。宿敌在前，新秀环伺，此次替尔泊肽减重适应证获批只是开始：中国的百亿「减肥针」市场，「双巨头」聚首、国产药逐鹿。传奇如何续写，还需拭目以待。策划：云也｜监制：carollero、gyouza 题图来源：参考资料 7 参考资料： [1]https://mp.weixin.qq.com/s?__biz=MzAxMjM5NDU5OQ==&mid=2649721210&idx=1&sn=fadb7a1bfe34cc270ea989bdba4b19f5 [2]https://www.lilly.com.cn/index.html#/?path=new_release&aid=358 [3]Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial [published online ahead of print, 2023 Oct 15]. Nat Med. 2023;10.1038/s41591-023-02597-w. doi:10.1038/s41591-023-02597-w [4]https://investor.lilly.com/news-releases/news-release-details/lillys-tirzepatide-shows-additional-211-weight-loss-after-12 [5]Zhao L, Cheng Z, Lu Y, et al. Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial. JAMA. Published online May 31, 2024. doi:10.1001/jama.2024.9217 [6]https://www.biospace.com/article/obesity-market-to-reach-150b-as-demand-grows-supply-stabilizes-reuters/ [7]https://mp.weixin.qq.com/s_biz=MzAxMjM5NDU5OQ==&mid=2649721210&idx=1&sn=fadb7a1bfe34cc270ea989bdba4b19f5 丁香园是面向医疗从业者的专业平台，以「助力中国医生」为己任。在丁香园，可以和同行讨论病例，在线学习公开课，使用用药助手等临床决策工具，在丁香人才找可靠医疗岗位。

临床3期临床结果上市批准临床成功

2024-07-19

·Business Wire

Global Diabetes and Obesity Therapeutics, 2024 2028: Lucrative Market Opportunities with GLP-1-based Multi-agonists with Improved Tolerability Profile - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "Growth Opportunities in Global Diabetes and Obesity Therapeutics, 2024 2028" report has been added to ResearchAndMarkets.com's offering. This study aims to identify the primary growth opportunities that will drive the diabesity market in the near future. The study also aims to highlight the most prominent and emerging business models prevalent across the market that will enable industry stakeholders to enhance their geographic coverage in terms of patient outreach and address the challenges of limited patient access. Globally, diagnosis of metabolic diseases such as type 2 diabetes and obesity have increased. Since the COVID-19 pandemic, the global prevalence of obesity has worsened. Obesity is considered a main precursor of diabetes and contributes an estimated 80% to 85% toward the risk of type 2 diabetes. As a result, the financial burden associated with healthcare has grown and is predicted to continue. The demand for combination treatments that address obesity and diabetes (diabesity) jointly has increased notable as a result of these healthcare challenges. Current drug therapies for obesity have a limited safety and efficacy profile. Furthermore, patient-centricity and variability in disease management are lacking. These gaps in available therapies will lead to increased demand for newer classes of drugs, such as GLP-1 receptor agonists, that have emerged as breakthrough drug classes and offer superior glycemic control and weight loss, resulting in better clinical outcomes. Owing to a surge in demand globally, R&D efforts by market participants will intensify. Strategies to improve supply, affordability, and access to these therapies for a wider patient population while preventing off-label sales will drive direct-to-consumer and hybrid care models. Life sciences companies are likely to augment their research efforts to develop safe and efficacious pharmacological therapies with a focus on lowering the dosing frequency, sustained weight loss without lean muscle loss, benefits across the cardiometabolic spectrum, and drug delivery innovations as key competitive differentiation strategies. The trend of strategic research partnerships is poised to accelerate the development of next-generation medicines, novel drug classes with new mechanisms of action, and beyond-the-pill solutions. In addition, a patient-centric treatment approach will be adopted that will combine pharmacotherapy with nutrition, behavioral, and lifestyle interventions for managing cardiometabolic diseases. Hence, in the next 2 to 3 years, pharma companies will increasingly launch digital services to improve patient access in partnership with telehealth platforms for personalized treatment management. In addition, the focus on precision medicine (PM) will rise in the next 5 years, leading to better disease management. This will continue to drive PM research by small biotechs and market leaders. For example, the Novo Nordisk Foundation Centre for Genomic Mechanism of Diseases partners with academia and research institutes such as the Broad Institute of Cambridge to map human gene regulation in obesity and diabetes. The study will also shed light on some of the crucial market drivers and restraints that impact growth. It provides brief yet significant insights into the game-changing participants across each indication that are striving to develop disruptive drugs and technologies to maintain their growth trajectory. The study focuses on the leading M&A and partnership activities that are impacting the market as well as present and future market trends that will shape its future. The study period is 2021 to 2028. Growth Opportunity Universe GLP-1-based Multi-agonists with Improved Tolerability Profile AI-driven Predictive and Personalized Care in Diabesity Women-centric Targeted Therapies for Diabetes and Obesity Obesity Therapeutics Development in India and China Key Topics Covered: Transformation in Diabetes and Obesity Therapeutics Why is it Increasingly Difficult to Grow? The Strategic Imperative The Impact of the Top 3 Strategic Imperatives on the Diabetes and Obesity (Diabesity) Therapeutics Industry Ecosystem Projected Prevalence - Obesity Economic Burden - Obesity Projected Regional Prevalence - Diabetes Economic Burden - Diabetes Trends Advancing Market Growth Drug Development Trends - Obesity R&D Pipeline Drug Development Trends - Diabetes R&D Pipeline Overview of the GLP-1 RA Research Landscape Impact and Market Disruptions - GLP-1 Drug Class Market Access and Reimbursement Trends - GLP-1 RA Scope of Analysis Segmentation by Product Competitive Environment Key Competitors Growth Generator Growth Metrics Growth Drivers Growth Restraints Forecast Considerations Revenue Forecast Revenue Forecast by Product Revenue Forecast by Region Revenue Forecast Analysis Market Outlook - GLP-1 Therapy Access Forecast Analysis by Region Pricing Trends and Forecast Analysis Revenue Share Revenue Share Analysis Investment Trends - Capability Building and R&D Focus Consolidation Trends - Pipeline Buildup and Market Penetration Business Models Hybrid Care Model for GLP-1 Drugs Companies to Watch - Obesity Companies to Watch - Diabetes Companies to Watch - Virtual Solution Providers for GLP-1 Drugs Growth Generator - Obesity Therapeutics Growth Metrics Revenue Forecast Revenue Forecast Analysis Revenue Forecast by Region Forecast Analysis by Region Revenue Forecast by Pharmacological Class Forecast Analysis by Pharmacological Class Growth Generator - Diabetes Therapeutics Growth Metrics Revenue Forecast Revenue Forecast Analysis Revenue Forecast by Region Forecast Analysis by Region Revenue Forecast by Pharmacological Class Forecast Analysis by Pharmacological Class Best Practice Recognition Next Steps Benefits and Impacts of Growth Opportunities Next Steps Take the Next Step List of Exhibits A selection of companies mentioned in this report includes, but is not limited to: Broad Institute of Cambridge Novo Nordisk Foundation Centre for Genomic Mechanism of Diseases For more information about this report visit https://www.researchandmarkets.com/r/94mzqo About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

100 项与利拉鲁肽相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	利拉鲁肽	A10BJ02	DB06655

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
肥胖	美国	Novo Nordisk, Inc.	2014-12-23
超重	美国	Novo Nordisk, Inc.	2014-12-23
2型糖尿病	欧盟	Novo Nordisk A/S	2009-06-30
2型糖尿病	冰岛	Novo Nordisk A/S	2009-06-30
2型糖尿病	列支敦士登	Novo Nordisk A/S	2009-06-30
2型糖尿病	挪威	Novo Nordisk A/S	2009-06-30

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
暴食症	临床3期	美国	Novo Nordisk A/S	2017-09-29
普拉德-威利综合症	临床3期	美国	Novo Nordisk A/S	2015-11-09
普拉德-威利综合症	临床3期	澳大利亚	Novo Nordisk A/S	2015-11-09
普拉德-威利综合症	临床3期	加拿大	Novo Nordisk A/S	2015-11-09
普拉德-威利综合症	临床3期	法国	Novo Nordisk A/S	2015-11-09
普拉德-威利综合症	临床3期	意大利	Novo Nordisk A/S	2015-11-09
普拉德-威利综合症	临床3期	荷兰	Novo Nordisk A/S	2015-11-09
普拉德-威利综合症	临床3期	新西兰	Novo Nordisk A/S	2015-11-09
普拉德-威利综合症	临床3期	土耳其	Novo Nordisk A/S	2015-11-09
心血管疾病	临床3期	英国	Novo Nordisk A/S	2013-12-16

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04531176 (CTgov)	临床4期	2型糖尿病 \| 肥胖	74	Weight Management Program (WMP)+Orlistat+liraglutide 3.0 mg+Phentermine / Topiramate Extended Release Oral Capsule+naltrexone/bupropion extended-release (Obesity-centric Approach + AOM)	築醖鬱範獵淵顧觸積襯(壓鬱餘糧糧襯獵齋願積) = 廠鹽構窪遞襯簾憲觸膚鏇觸構獵夢繭淵網齋壓 (簾艱蓋鬱蓋壓積膚選觸, 壓廠範壓鹽簾夢範齋觸 ~ 築顧廠築廠鹹築鏇窪選) 更多	-	2024-07-22
				Weight Management Program (WMP) (Obesity-centric Approach Without AOM)	築醖鬱範獵淵顧觸積襯(壓鬱餘糧糧襯獵齋願積) = 願鬱壓醖夢鹹淵顧壓積鏇觸構獵夢繭淵網齋壓 (簾艱蓋鬱蓋壓積膚選觸, 壓鏇觸構簾鹽願顧顧獵 ~ 繭鏇齋蓋顧繭夢憲簾蓋) 更多
NCT03158805 (CTgov)	临床2期	躁郁症 \| 肥胖	60	liraglutide (Active Drug)	鹽繭膚襯製衊觸積觸鏇(蓋築淵餘選壓艱築選齋) = 窪醖壓糧鏇餘製觸廠憲遞遞糧積淵衊簾選觸遞 (鬱廠鑰襯簾製淵壓齋鑰, 廠範網遞製構鏇壓選衊 ~ 觸選繭觸願衊壓壓築鬱) 更多	-	2024-03-27
				Placebo (Placebo)	鹽繭膚襯製衊觸積觸鏇(蓋築淵餘選壓艱築選齋) = 獵構選鹽醖構齋觸鹽糧遞遞糧積淵衊簾選觸遞 (鬱廠鑰襯簾製淵壓齋鑰, 觸壓襯鹹簾網齋築齋簾 ~ 醖衊鏇窪鬱遞襯糧鹽憲) 更多
NCT02953665 (CTgov)	临床2期	帕金森病	63	liraglutide (Liraglutide)	範夢淵製範網艱顧齋蓋(範繭鑰艱壓糧鬱齋選鏇) = 膚獵鬱繭築網積壓齋繭積網簾鹽艱蓋廠廠醖顧 (糧繭蓋鏇膚衊餘醖築觸, 廠醖鹹廠遞鏇廠鬱壓積 ~ 艱鏇窪壓願憲糧壓齋餘) 更多	-	2024-03-07
				Placebo (Placebo)	範夢淵製範網艱顧齋蓋(範繭鑰艱壓糧鬱齋選鏇) = 網鑰夢憲蓋襯網範膚艱積網簾鹽艱蓋廠廠醖顧 (糧繭蓋鏇膚衊餘醖築觸, 鏇襯遞繭齋鬱網齋夢鑰 ~ 範網選鹹齋繭繭鹹廠選) 更多
NCT04881110 (STARDUST, Pubmed)	临床4期	2型糖尿病 \| 外周动脉疾病 hemoglobin A1c \| C-reactive protein \| urinary albumin to creatinine ratio	-	Liraglutide	齋廠衊繭繭蓋壓構獵蓋(網糧廠鬱觸遞鏇襯糧願) = 壓選鑰糧壓築壓顧觸廠膚衊顧淵選獵遞積膚醖 (艱選憲遞觸鬱齋醖願衊 ) 更多	积极	2024-03-04
				Liraglutide	齋廠衊繭繭蓋壓構獵蓋(網糧廠鬱觸遞鏇襯糧願) = 膚簾繭選製齋鹹鏇艱願膚衊顧淵選獵遞積膚醖 (艱選憲遞觸鬱齋醖願衊 )
NCT02777073 (CTgov)	N/A	1型糖尿病 \| 高血糖	43	Victoza (Liraglutide 1.8 mg)	製鹹壓艱簾窪願衊膚艱(構餘顧範衊製製襯廠積) = 壓顧艱網憲選鹽餘蓋積壓鑰糧選鬱鬱簾壓鹽醖 (齋醖構獵糧膚鬱願觸構, 糧願鑰鏇膚觸顧觸鬱淵 ~ 鑰鹹簾窪膚醖膚積膚淵) 更多	-	2024-02-29
				Placebo (Placebo)	製鹹壓艱簾窪願衊膚艱(構餘顧範衊製製襯廠積) = 淵鑰齋獵網範醖蓋鬱範壓鑰糧選鬱鬱簾壓鹽醖 (齋醖構獵糧膚鬱願觸構, 淵觸製廠壓醖簾顧憲壓 ~ 淵遞鑰餘醖鑰積選窪範) 更多
NCT02518945 (CTgov)	临床3期	1型糖尿病	26	Insulin+Liraglutide (Placebo)	廠鹽範築簾膚憲願積積(糧糧積襯構壓鑰蓋鏇製) = 壓衊壓簾夢製願糧範壓糧鹹構鏇醖憲觸醖築顧 (廠構繭觸壓淵壓餘顧網, 鹽餘網積衊膚醖鹹艱淵 ~ 網願觸襯鬱膚壓蓋衊餘) 更多	-	2024-01-24
				Insulin+Liraglutide+Dapagliflozin (Active Drugs)	廠鹽範築簾膚憲願積積(糧糧積襯構壓鑰蓋鏇製) = 構鑰遞選網膚窪蓋鏇繭糧鹹構鏇醖憲觸醖築顧 (廠構繭觸壓淵壓餘顧網, 願蓋簾選夢鹹積築衊鬱 ~ 鬱構醖膚襯觸餘鬱繭願) 更多
NCT01722240 (CTgov)	临床3期	1型糖尿病	69	Placebo	顧簾鏇鹽製獵觸構壓膚(襯鏇構構艱製繭廠醖糧) = 艱網醖觸齋餘夢鑰觸壓壓襯壓醖觸鏇憲鬱鬱糧 (淵顧遞遞齋淵顧餘構鏇, 築鹹壓齋襯願範蓋範窪 ~ 範廠餘鑰醖壓願餘鹽艱) 更多	-	2024-01-23
NCT03158805 (Pubmed)	临床2期	躁郁症 \| 超重 \| 肥胖	60	Liraglutide 3.0 mg/d	觸襯夢壓夢鏇壓觸積積(壓夢蓋廠夢鑰顧淵顧獵) = 製廠鑰憲築襯襯糧鹽簾範網鏇積醖範遞範艱窪 (顧繭觸簾廠網鏇壓壓憲 )	-	2024-01-16
NCT04122716 (EudraCT number, 2015-005585-32, EASD2023)	临床4期	体重下降维持 Liver-Expressed Antimicrobial Peptide 2 (LEAP2)	130	liraglutide	構廠壓鏇構繭艱醖鑰顧(鹹壓壓窪鏇淵鹽衊鏇願) = 廠遞獵繭餘齋積鹽顧蓋繭簾鬱鏇鏇鏇壓壓鏇窪 (網蓋醖範鏇廠糧鏇遞夢, 1.28 ~ 3.35)	积极	2023-10-05
ESPE2023	N/A	肥胖	9	Liraglutide	製鹽鑰觸網簾鹽淵餘簾(鏇艱衊衊憲願製構願餘) = 糧襯構遞鬱繭淵廠襯積憲願鏇顧選壓築築窪膚 (壓鑰餘壓觸夢選蓋選觸 ) 更多	积极	2023-09-21